Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Systemic, perioperative management of muscle-invasive bladder cancer and future horizons.

Nature reviews. Clinical oncology - 1 Apr 2017

Funt Samuel A, Rosenberg Jonathan E

Abstract excerpt

Many patients diagnosed with muscle-invasive bladder cancer (MIBC) will develop distant metastatic disease. Over the past three decades, perioperative cisplatin-based chemotherapy has been investigated for its ability to reduce the number of deaths from bladder cancer. Insufficient evidence is available to fully support the use of such chemotherapy in the adjuvant setting; however, neoadjuvant cisplatin-based...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Preoperative Care
Share to Chemotherapy, Adjuvant
Share to Cisplatin

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Deoxycytidine

Share to Evidence-Based Medicine

Share to Gemcitabine

Share to Lymphatic Metastasis

Share to Randomized Controlled Trials as Topic

Source

Open in PubMed Open full text

Identifiers

PMID: 27874062
DOI: 10.1038/nrclinonc.2016.188
PMCID: PMC6054138

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Systemic, perioperative management of muscle-invasive bladder cancer and future horizons.PMID 27874062Read ↗

Resistance to Platinum-Based Chemotherapy in Muscle-Invasive Bladder Cancer: Genetic and Immune Determinants and Implications for Treatment Sequencing — A Case SeriesSemantic proximity Read ↗

New and promising strategies in the management of bladder cancer.Semantic proximity Read ↗

Molecular correlates of cisplatin-based chemotherapy response in muscle invasive bladder cancer by integrated multi-omics analysis.Semantic proximity Read ↗

Complete Response To Tislelizumab In A Muscle-Invasive Urothelial Carcinoma After Surgery Associated With Tumor Mutational Burden High: A Case ReportSemantic proximity Read ↗

Genomic and Therapeutic Landscape of Non-muscle-invasive Bladder Cancer.Semantic proximity Read ↗

Molecular subtyping of invasive bladder cancer: time to divide and rule?Semantic proximity Read ↗

The consensus molecular classification of muscle-invasive bladder cancerSemantic proximity Read ↗

Systemic chemotherapy for patients with bladder cancer--current controversies and future directions.Semantic proximity Read ↗

Tumor-myeloid crosstalk drives therapy resistance in localized bladder cancerSemantic proximity Read ↗

Identification of distinct basal and luminal subtypes of muscle-invasive bladder cancer with different sensitivities to frontline chemotherapy.Semantic proximity Read ↗

Immunotherapy in Bladder Cancer: A Systematic Review of Clinical Trials and Therapeutic AdvancesSemantic proximity Read ↗

Integrating molecular subtype and CD8+ T cells infiltration to predict treatment response and survival in muscle-invasive bladder cancerSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.